Zevra Therapeutics Future Growth
Future criteria checks 6/6
Zevra Therapeutics is forecast to grow earnings and revenue by 63.6% and 42% per annum respectively. EPS is expected to grow by 63.3% per annum. Return on equity is forecast to be 190.8% in 3 years.
Key information
63.6%
Earnings growth rate
63.3%
EPS growth rate
Pharmaceuticals earnings growth | 20.5% |
Revenue growth rate | 42.0% |
Future return on equity | 190.8% |
Analyst coverage | Good |
Last updated | 16 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 159 | 28 | 12 | 14 | 5 |
12/31/2025 | 91 | -20 | -23 | -30 | 6 |
12/31/2024 | 29 | -69 | -42 | -50 | 6 |
12/31/2023 | 27 | -46 | -34 | -34 | N/A |
9/30/2023 | 17 | -40 | -22 | -22 | N/A |
6/30/2023 | 17 | -32 | -24 | -24 | N/A |
3/31/2023 | 9 | -51 | -19 | -19 | N/A |
12/31/2022 | 10 | -27 | -19 | -19 | N/A |
9/30/2022 | 11 | -35 | -15 | -15 | N/A |
6/30/2022 | 10 | -30 | -11 | -11 | N/A |
3/31/2022 | 20 | -17 | 9 | 9 | N/A |
12/31/2021 | 29 | -63 | 10 | 10 | N/A |
9/30/2021 | 28 | -65 | 10 | 10 | N/A |
6/30/2021 | 28 | -66 | 12 | 12 | N/A |
3/31/2021 | 23 | -55 | -3 | -3 | N/A |
12/31/2020 | 13 | -13 | -2 | -2 | N/A |
9/30/2020 | 12 | -14 | -4 | -4 | N/A |
6/30/2020 | 22 | -8 | -5 | -5 | N/A |
3/31/2020 | 15 | -18 | -15 | -15 | N/A |
12/31/2019 | 13 | -25 | -24 | -24 | N/A |
9/30/2019 | 11 | -24 | -36 | -36 | N/A |
6/30/2019 | N/A | -42 | -49 | -49 | N/A |
3/31/2019 | N/A | -43 | -51 | -51 | N/A |
12/31/2018 | N/A | -56 | -54 | -54 | N/A |
9/30/2018 | N/A | -62 | -46 | -46 | N/A |
6/30/2018 | N/A | -57 | -40 | -40 | N/A |
3/31/2018 | N/A | -53 | -38 | -38 | N/A |
12/31/2017 | N/A | -43 | -33 | -33 | N/A |
9/30/2017 | N/A | -43 | N/A | -36 | N/A |
6/30/2017 | N/A | -45 | N/A | -34 | N/A |
3/31/2017 | N/A | -30 | N/A | -35 | N/A |
12/31/2016 | N/A | -17 | N/A | -30 | N/A |
9/30/2016 | N/A | -16 | N/A | -27 | N/A |
6/30/2016 | N/A | -13 | N/A | -23 | N/A |
3/31/2016 | N/A | -52 | N/A | -20 | N/A |
12/31/2015 | N/A | -55 | N/A | -20 | N/A |
9/30/2015 | N/A | -57 | N/A | -21 | N/A |
6/30/2015 | N/A | -55 | N/A | -20 | N/A |
3/31/2015 | N/A | -29 | N/A | -18 | N/A |
12/31/2014 | N/A | -24 | N/A | -15 | N/A |
9/30/2014 | N/A | -14 | N/A | -9 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1GDA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.6%).
Earnings vs Market: 1GDA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 1GDA is expected to become profitable in the next 3 years.
Revenue vs Market: 1GDA's revenue (42% per year) is forecast to grow faster than the German market (5.4% per year).
High Growth Revenue: 1GDA's revenue (42% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1GDA's Return on Equity is forecast to be very high in 3 years time (190.8%).